For individuals and couples experiencing fertility challenges, understanding the possible factors affecting conception and pregnancy can be an important part of the healthcare journey.
Fertility and pregnancy outcomes can be influenced by many factors, including ovulation, sperm health, reproductive anatomy, hormonal conditions, genetics, and other medical factors. In some cases, immune-related mechanisms may also be investigated.
One emerging area of research involves β2GPI NeoSelf antibodies and their potential relationship with reproductive conditions such as recurrent pregnancy loss (RPL) and recurrent implantation failure (RIF).
The β2GPI NeoSelf Antibody Test, developed by AOI Biosciences (AOI Bio), is a blood test designed to detect these antibodies. AOI Bio reports that the test is intended to provide additional information during the evaluation of certain reproductive conditions.
But what exactly are β2GPI NeoSelf antibodies? How does the test work? And where might it fit within fertility care?
Let's take a closer look.
What Is the β2GPI NeoSelf Antibody Test?
The β2GPI NeoSelf Antibody Test is a blood test that detects antibodies directed against a structure involving β2-glycoprotein I (β2GPI) and HLA-DR.
β2GPI is a protein involved in several biological processes and has long been studied in connection with antiphospholipid syndrome (APS) and pregnancy complications. The NeoSelf concept focuses on antibodies that recognize a particular form of the β2GPI/HLA-DR complex. AOI Bio has developed a test intended to detect these antibodies with high sensitivity. The test is being investigated in relation to reproductive conditions, including recurrent pregnancy loss and recurrent implantation failure.
Importantly, a NeoSelf antibody test result does not independently establish the cause of infertility or pregnancy loss. AOI Bio describes the test as an aid to diagnosis rather than a definitive diagnostic test. Results therefore need to be interpreted alongside a person's medical history, other investigations, and clinical findings.
What Are β2GPI NeoSelf Antibodies?
To understand the test, it helps to first understand antibodies. Antibodies are proteins produced by the immune system that recognize specific targets. In autoimmune conditions, antibodies can sometimes react against structures associated with the body's own tissues.
β2GPI NeoSelf antibodies are antibodies that recognize a specific complex involving β2GPI and HLA-DR. The NeoSelf theory proposes that changes in the way these molecules are presented to the immune system can create a target that is recognized as "non-self," despite being made from the body's own components.
Research has investigated whether these antibodies may be associated with processes such as vascular inflammation and thrombosis, which could be relevant to some reproductive complications. However, the biological mechanisms and their clinical significance continue to be investigated. This is an important distinction: the presence of an antibody is not, by itself, proof that it caused a person's fertility problem.
How Is the NeoSelf Test Connected to Fertility?
Fertility challenges can have many possible causes, and not every person experiencing infertility or pregnancy loss will have the same underlying factors.
Research conducted by AOI Bio and collaborating researchers has investigated β2GPI NeoSelf antibodies in people experiencing conditions including:
- Recurrent pregnancy loss (RPL): repeated pregnancy losses.
- Recurrent implantation failure (RIF): repeated unsuccessful implantation following assisted reproductive treatment.
- Certain infertility cases: particularly cases in which other clinical factors may not fully explain the fertility challenge.
AOI Bio reports that research has found higher rates of NeoSelf antibody positivity in certain groups, including people with RIF and some individuals with infertility. However, these findings come from specific study populations and should not be interpreted as meaning that NeoSelf antibodies are responsible for all cases of infertility or pregnancy loss.
More recent research is also examining possible relationships between NeoSelf antibodies and the uterine environment, including the endometrial microbiome and chronic endometritis. These areas remain under investigation.
Who Might Discuss NeoSelf Antibody Testing With a Healthcare Professional?
The test may be discussed as part of a broader reproductive health assessment, particularly for individuals with a relevant medical history.
Potential situations may include:
Recurrent pregnancy loss
People who have experienced repeated pregnancy losses may undergo investigations to identify possible contributing factors. Depending on the individual's history, a healthcare professional may consider whether additional testing, including emerging immune-related tests, is appropriate.
Recurrent implantation failure
Individuals who have experienced repeated unsuccessful embryo implantation during assisted reproductive treatment may also undergo additional investigations. Research has explored the presence of β2GPI NeoSelf antibodies in people experiencing RIF.
Unexplained fertility challenges
For some individuals, standard fertility investigations may not fully explain difficulties with conception or pregnancy. In such situations, a fertility specialist may discuss additional investigations based on the individual's medical history and clinical circumstances. Testing should not be viewed as a universal fertility screening test. Whether it is appropriate depends on the individual's situation and the advice of their healthcare professional.
How Does the NeoSelf Testing Process Work?
The NeoSelf Antibody Test is performed using a blood sample.
The general process may include:
1. Consultation
Discuss your reproductive history with a qualified healthcare professional and ask whether NeoSelf antibody testing may be appropriate.
2. Blood sample collection
A blood sample is collected through a medical institution offering the test.
3. Laboratory analysis
The sample is tested for β2GPI NeoSelf antibodies.
4. Results review
A healthcare professional interprets the result alongside your medical history and other clinical investigations. The exact process, availability, turnaround time, and cost can vary between healthcare institutions. Patients should confirm these details directly with the relevant clinic or medical provider.
What Does a Positive Result Mean?
A positive result means β2GPI NeoSelf antibodies were detected in the blood sample. However, a positive result should not be interpreted as proof that the antibodies are the sole cause of infertility, implantation failure, or pregnancy loss. Instead, the result may provide an additional piece of information for a healthcare professional to consider alongside other clinical findings.
AOI Bio has reported clinical research investigating outcomes among patients who tested positive and subsequently received medical intervention. Some studies have reported differences in pregnancy or live-birth outcomes following treatment. However, these findings should be interpreted in the context of the individual studies, their populations, treatment approaches, and limitations. Importantly, the appropriate treatment depends on the individual's clinical circumstances and should be determined by a qualified healthcare professional.
Depending on the individual's clinical circumstances and medical assessment, treatment may include low-dose aspirin (LDA) and/or heparin, an anticoagulant (blood thinner). These medications may be used in specific patients with antiphospholipid syndrome (APS) or other relevant clinical indications. However, a positive β2GPI NeoSelf result alone does not mean that medication is required. A qualified healthcare professional should decide whether to use LDA, heparin, or both after considering the individual's medical history, clinical findings, other test results, and potential risks.
A positive test does not guarantee pregnancy, implantation, or a live birth. Similarly, a healthcare professional should decide whether to use medications such as antiplatelet or anticoagulant therapies after considering the individual's medical history and risks.
Why Is Fertility Testing Important?
Fertility can be a complex and deeply personal healthcare journey. For people experiencing recurrent pregnancy loss or unsuccessful fertility treatment, understanding the possible factors involved can help guide conversations with their healthcare providers.
Emerging tests such as the β2GPI NeoSelf Antibody Test are one area of ongoing research in reproductive medicine. The test may provide additional information in selected clinical situations, but it should be considered alongside established fertility investigations rather than as a replacement for a comprehensive fertility assessment.
It is also important to remember that fertility challenges are often multifactorial. A single test cannot explain every case of infertility or pregnancy loss.
NeoSelf Antibody Testing in Malaysia
AOI Biosciences announced the launch of its β2GPI NeoSelf Antibody Test services in Malaysia on July 9, 2025. The company stated that the test became available through multiple medical institutions in Malaysia.
Because availability and participating institutions may change over time, individuals interested in testing should contact a fertility clinic or relevant medical institution directly to confirm:
- Whether the test is currently available
- Whether a consultation is required
- Where the blood sample can be collected
- Expected testing and turnaround time
- Current costs
- How the results will be interpreted within their individual care plan
AOI Bio also provides information for individuals looking for medical institutions that offer the test.
What Does Current Research Tell Us?
Research into β2GPI NeoSelf antibodies is still developing. AOI Bio reports studies investigating the relationship between these antibodies and recurrent pregnancy loss, recurrent implantation failure, infertility, and other reproductive outcomes.
Research is continuing. For example, a study published in 2026 investigated relationships between NeoSelf antibodies, the endometrial microbiome, and chronic endometritis in women with recurrent implantation failure and recurrent pregnancy loss. The researchers suggested that NeoSelf antibodies may have potential as a biomarker in this context, but further research is needed to clarify their clinical significance. This distinction between research findings and established clinical practice is important when considering any emerging medical test.
Conclusion
Understanding fertility and reproductive health involves looking at multiple factors that may influence conception, implantation, pregnancy, and pregnancy outcomes. The β2GPI NeoSelf Antibody Test is an emerging blood test that investigates antibodies targeting a β2GPI/HLA-DR complex. Research has explored its potential relationship with recurrent pregnancy loss, recurrent implantation failure, and certain infertility cases.
For some individuals, testing may provide additional information that can be discussed with a fertility specialist. However, the test should be interpreted within the context of a person's complete medical history and other investigations. If you are experiencing infertility, recurrent implantation failure, or recurrent pregnancy loss, speak with a qualified healthcare professional about which investigations may be appropriate for you.
At LUMIROUS, we believe that accessible and understandable healthcare information can help people ask informed questions, understand available options, and have more meaningful conversations with their healthcare providers.
Medical Disclaimer
This article is intended for general educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
The β2GPI NeoSelf Antibody Test is an emerging diagnostic approach, and research into its clinical applications is ongoing. A test result should be interpreted by a qualified healthcare professional in the context of an individual's medical history and other clinical findings.
Treatment decisions should always be made with a qualified healthcare professional. Test availability, clinical practice, and medical recommendations may vary by location and over time.
Contact
Should you have any queries, please contact us at:
Email: enquiry@lumirous.com
Website:www.lumirous.com
LUMIROUS Sdn. Bhd.
D-18-21, Tower D, Exsim Tower, Millerz Square
Old Klang Road, 58000 Kuala Lumpur, Malaysia
